USA - NASDAQ:SRRK - US80706P1030 - Common Stock
The current stock price of SRRK is 32.34 USD. In the past month the price increased by 2.6%. In the past year, price increased by 244.41%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.42 | 382.04B | ||
AMGN | AMGEN INC | 12.52 | 147.02B | ||
GILD | GILEAD SCIENCES INC | 14.32 | 137.56B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 100.34B | ||
REGN | REGENERON PHARMACEUTICALS | 12.6 | 60.95B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.46B | ||
ARGX | ARGENX SE - ADR | 81.16 | 46.04B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.71 | 38.90B | ||
INSM | INSMED INC | N/A | 30.60B | ||
NTRA | NATERA INC | N/A | 24.02B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.86B | ||
BIIB | BIOGEN INC | 8.97 | 21.06B |
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2018-05-24. The company is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
SCHOLAR ROCK HOLDING CORP
301 Binney Street, 3rd Floor
Cambridge MASSACHUSETTS 02142 US
CEO: Stuart A. Kingsley
Employees: 196
Phone: 18572593860
The current stock price of SRRK is 32.34 USD. The price decreased by -3.95% in the last trading session.
The exchange symbol of SCHOLAR ROCK HOLDING CORP is SRRK and it is listed on the Nasdaq exchange.
SRRK stock is listed on the Nasdaq exchange.
16 analysts have analysed SRRK and the average price target is 51.58 USD. This implies a price increase of 59.5% is expected in the next year compared to the current price of 32.34. Check the SCHOLAR ROCK HOLDING CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SCHOLAR ROCK HOLDING CORP (SRRK) has a market capitalization of 3.11B USD. This makes SRRK a Mid Cap stock.
SCHOLAR ROCK HOLDING CORP (SRRK) currently has 196 employees.
SCHOLAR ROCK HOLDING CORP (SRRK) has a support level at 31.41 and a resistance level at 35.07. Check the full technical report for a detailed analysis of SRRK support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SRRK does not pay a dividend.
SCHOLAR ROCK HOLDING CORP (SRRK) will report earnings on 2025-11-10, before the market open.
SCHOLAR ROCK HOLDING CORP (SRRK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.92).
The outstanding short interest for SCHOLAR ROCK HOLDING CORP (SRRK) is 18.36% of its float. Check the ownership tab for more information on the SRRK short interest.
ChartMill assigns a technical rating of 4 / 10 to SRRK. When comparing the yearly performance of all stocks, SRRK is one of the better performing stocks in the market, outperforming 97.16% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to SRRK. The financial health of SRRK is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months SRRK reported a non-GAAP Earnings per Share(EPS) of -2.92. The EPS decreased by -31.53% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -92.84% | ||
ROE | -135.32% | ||
Debt/Equity | 0.21 |
16 analysts have analysed SRRK and the average price target is 51.58 USD. This implies a price increase of 59.5% is expected in the next year compared to the current price of 32.34.